Last reviewed · How we verify

NCT05630898: cCMV

Congenital Cytomegalovirus: Prevalence in Buenos Aires City (cCMV Prevalence)

Status unknown Last updated 30 November 2022
What this trial tests

trial testing CMV PCR in Congenital Cytomegalovirus in 3,000 participants. Status unknown.

Timeline
1 April 2023
Primary endpoint
30 September 2024
30 December 2024

Quick facts

Lead sponsorHospital de Niños R. Gutierrez de Buenos Aires
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment3,000
Start date1 April 2023
Primary completion30 September 2024
Estimated completion30 December 2024
Sites3 locations across Argentina

Drugs / interventions tested

Conditions studied

Sponsor

Hospital de Niños R. Gutierrez de Buenos Aires

Who can join

Adults 1 Day to 21 Days, any sex, with Congenital Cytomegalovirus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to recognise the prevalnce of congenital cytomegalovirus (cCMV) and to follow up positive babies until 12 months The main questions it aims to answer are: pevalence of cCMV, cCMV clinicals outcomes during the first year of life. Participants will be screened with a salive swab for CMV DNA. Babies with positive results will be follow up for one year.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of CMV PCR

Trials testing the same drug.

Other Hospital de Niños R. Gutierrez de Buenos Aires trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05630898.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing